U.S. Markets closed

Wall Street Recommendations for Merck & Co. before Earnings

Mike Benson
Wall Street Recommendations for Merck & Co. before Earnings

Wall Street analysts expect Merck & Co.’s (MRK) top line to increase 7.1% to $10.1 billion for 1Q18, compared to revenues of $9.4 billion for 1Q17. The revenues for Merck are expected to be driven by strong sales of Keytruda and other products, partially offset by lower sales of Remicade, Zetia, Vytorin. Merck & Co.’s stock price has decreased nearly 4.9% over the last 12 months, but it increased ~5.7% in 2018 year-to-date.